Cancer Genetics Inc. (CGIX) Director John Pappajohn Acquires 100,000 Shares
Cancer Genetics Inc. (NASDAQ:CGIX) Director John Pappajohn purchased 100,000 shares of the business’s stock in a transaction dated Monday, November 28th. The shares were purchased at an average price of $1.45 per share, for a total transaction of $145,000.00. Following the acquisition, the director now owns 2,420,709 shares of the company’s stock, valued at $3,510,028.05. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
John Pappajohn also recently made the following trade(s):
- On Monday, November 14th, John Pappajohn purchased 31,100 shares of Cancer Genetics stock. The shares were purchased at an average price of $1.48 per share, for a total transaction of $46,028.00.
Shares of Cancer Genetics Inc. (NASDAQ:CGIX) traded up 3.23% during midday trading on Tuesday, reaching $1.60. 122,016 shares of the company traded hands. The company has a 50 day moving average price of $1.52 and a 200 day moving average price of $1.91. The company’s market capitalization is $30.22 million. Cancer Genetics Inc. has a 1-year low of $1.10 and a 1-year high of $3.48.
Cancer Genetics (NASDAQ:CGIX) last posted its quarterly earnings data on Thursday, November 10th. The company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.05. Cancer Genetics had a negative return on equity of 63.26% and a negative net margin of 74.07%. The firm earned $6.80 million during the quarter, compared to analyst estimates of $6.93 million. During the same period last year, the company posted ($0.56) EPS. The business’s quarterly revenue was up 70.0% on a year-over-year basis. On average, analysts expect that Cancer Genetics Inc. will post ($1.17) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/29/cancer-genetics-inc-cgix-director-john-pappajohn-acquires-100000-shares.html.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Eagle Global Advisors LLC raised its position in Cancer Genetics by 69.3% in the second quarter. Eagle Global Advisors LLC now owns 84,320 shares of the company’s stock valued at $168,000 after buying an additional 34,510 shares during the period. Sabby Management LLC raised its stake in shares of Cancer Genetics by 145.5% in the second quarter. Sabby Management LLC now owns 199,580 shares of the company’s stock worth $397,000 after buying an additional 118,280 shares during the last quarter. Fairbanks Capital Management Inc. purchased a new stake in shares of Cancer Genetics during the second quarter worth approximately $464,000. Anson Funds Management LP purchased a new stake in shares of Cancer Genetics during the third quarter worth approximately $476,000. Finally, Vanguard Group Inc. raised its stake in shares of Cancer Genetics by 3.3% in the second quarter. Vanguard Group Inc. now owns 326,966 shares of the company’s stock worth $651,000 after buying an additional 10,328 shares during the last quarter. 12.19% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have recently commented on the stock. HC Wainwright assumed coverage on shares of Cancer Genetics in a report on Tuesday, September 27th. They set a “buy” rating and a $6.00 price target on the stock. Zacks Investment Research upgraded shares of Cancer Genetics from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a report on Tuesday, November 15th. Finally, Rodman & Renshaw assumed coverage on shares of Cancer Genetics in a report on Monday, September 26th. They set a “buy” rating and a $6.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $7.19.
About Cancer Genetics
Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
Receive News & Stock Ratings for Cancer Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc. and related stocks with our FREE daily email newsletter.